SAN DIEGO, August 21, 2026, 06:15 PDT —
- A shareholder case targets statements about Deramiocel’s trial analysis and FDA pathway.
- CAPR remains 65.3% below its July 24 close despite an FDA-driven rebound.
- Cash equals about 60% of market value, but spending rose sharply.
Capricor Therapeutics NASDAQ:CAPR faces a renewed legal overhang after law firms on Thursday repeated a September 28 lead-plaintiff deadline in a federal securities-fraud case. The complaint covers buyers from December 17, 2025, through July 26, 2026.
The lawsuit is important because it converts a clinical-data dispute into a second source of risk. Yet the drug review still dominates the valuation. CAPR closed Thursday at $6.84, unchanged in pre-market trading at 06:15 PDT, and remained 65.3% below its July 24 close.
| Date | CAPR close | Change or context |
|---|---|---|
| July 24 | $19.70 | Last close before FDA briefing documents |
| July 27 | $7.00 | Down 64.5% in one session |
| July 30 | $4.19 | Down 78.7% from July 24 |
| August 14 | $6.65 | Up 58.0% after FDA-path update |
| August 20 | $6.84 | Up 2.9% from August 14; still down 65.3% from July 24 |
The complaint alleges Capricor misled investors about changes to the statistical analysis plan for Deramiocel and whether the FDA had agreed to those changes. It names the Southern District of California case as Nkamga v. Capricor Therapeutics, Inc., No. 26-cv-04385. These are allegations. The court has not determined liability or damages.
The September deadline is procedural. It governs requests to lead the proposed class, not the merits. The market reaction occurred earlier, when FDA staff questioned post-study analysis changes and an advisory panel rejected the efficacy case by nine votes to three.
| Event | Date | Investor relevance |
|---|---|---|
| Class period begins | Dec. 17, 2025 | First purchase date covered by complaint |
| Class period ends | July 26, 2026 | One day before FDA documents moved the stock |
| FDA briefing documents | July 27 | Raised analysis and efficacy concerns |
| Advisory committee vote | July 29 | 9-3 against substantial evidence of effectiveness |
| FDA accepts more-data pathway | Aug. 13 | Company plans a 24-month data amendment |
| Lead-plaintiff deadline | Sept. 28 | Deadline to seek control of proposed class |
Capricor’s balance sheet offers a buffer. Cash, equivalents and marketable securities totaled $237.9 million at June 30. That equals 59.9% of Thursday’s $397.4 million market value.
The cushion is shrinking. Second-quarter operating expenses rose 54.9% year over year. A simple cash-to-quarterly-expense ratio gives 5.5 quarters, before interest income, working-capital changes or any change in launch spending. It is a yardstick, not company guidance.
| Metric | Latest | Comparison | Change |
|---|---|---|---|
| Cash and securities | $237.9m at June 30, 2026 | $318.1m at Dec. 31, 2025 | -25.2% |
| Q2 operating expenses | $42.9m | $27.7m in Q2 2025 | +54.9% |
| Q2 net loss | $40.7m | $25.9m in Q2 2025 | +57.1% |
| Cash / market value | 59.9% | $397.4m market value | Derived |
| Static cash runway | 5.5 quarters | Cash divided by Q2 expenses | Derived |
Chief Executive Linda Marbán said, “Our priority is, and always has been, to get Deramiocel to the patients and families living with Duchenne who need it most.” Capricor has paused non-Deramiocel work and moderated launch spending while the review remains unsettled. Company statement
The FDA is willing to review an amendment containing 24-month HOPE-3 data focused on upper-limb function. That development delayed the former August 22 action date and drove the August 14 rebound. It did not erase the panel’s concerns about cardiac benefit, missing data and altered analyses.
Analysts responded in opposite directions. Cantor Fitzgerald reopened a bullish case after the FDA update. Several firms had already moved to neutral or hold after the panel setback.
| Firm | Latest action | Rating | Price target |
|---|---|---|---|
| Cantor Fitzgerald | Aug. 14 upgrade | Overweight | $28 |
| B. Riley | July 31 maintain | Hold | $5 |
| Jones Trading | July 30 downgrade | Hold | Not stated |
| Piper Sandler | July 30 downgrade | Neutral | $2 |
| H.C. Wainwright | July 30 downgrade | Neutral | Not stated |
The $2-to-$28 target span is more than a normal forecasting disagreement. It reflects two incompatible paths: a longer review that preserves approval value, or a demand for more clinical work that extends losses and cash burn.
Risks: A favorable FDA response could make the lawsuit a secondary issue and push CAPR higher. An adverse response, a new trial requirement or damaging discovery in the case could depress the shares. Faster spending would also weaken the cash buffer.
The next useful signal is not another law-firm notice. Investors need the amendment timetable and a revised FDA action date. Until then, CAPR remains a regulatory binary with litigation attached.
Related articles: Pharmaceuticals
